FDA Authorizes Stryker SportSuite Vision, First Surgical Application for Apple Vision Pro

The U.S. Food and Drug Administration (FDA) has authorized Stryker SportSuite Vision, a software platform that turns Apple Vision Pro into a surgical display for hip arthroscopy. The clearance, granted through the De Novo pathway on 17 July 2026, is the first time the agency has authorized an intraoperative application built specifically for the Apple headset.

The authorized product is the software, not the headset. SportSuite Vision runs on a video see-through augmented reality display, so the surgeon keeps the operating room in view while virtual panels sit in front of it. Those panels carry the live arthroscopy camera feed, the HipCheck and HipMap planning tools, and CT imaging for reference only. Stryker describes the setup as “a customized surgical cockpit, built around you,” and argues that bringing those sources into one field of view reduces reliance on physical monitors and supports a more ergonomic sterile-field workflow.

What Stryker SportSuite Vision does

The cockpit draws on tools Stryker already sells for hip procedures. HipMap builds a patient-specific 3D model of the hip for preoperative planning. HipCheck guides intraoperative resection of cam lesions to a target alpha angle. SportSuite Vision places both, along with the live camera feed, inside the surgeon’s field of view.

Ad

A new device category

The decision, recorded as De Novo DEN250040, does more than clear a single product. It creates a new Class II device type under 21 CFR 888.1150 with product code SIT. Stryker Endoscopy of San Jose, California, requested the authorization; the agency received the submission on 2 September 2025 and granted it on 17 July 2026.

Future devices of the same type will follow the 510(k) pathway rather than a fresh De Novo. The indication is narrow. SportSuite Vision is cleared for the intraoperative display of arthroscopic video and medical imaging during femoroacetabular impingement and labral repair hip arthroscopy, plus the same information already shown by HipCheck and HipMap FAI Analysis. It is a prescription device, and the order requires that the surgeon use the virtual images alongside the traditional monitors used by the rest of the operating room staff.

What the FDA required

The agency did not treat the Apple Vision Pro headset as an unconstrained consumer device. The special controls cover cadaveric testing of procedural accuracy, simulated-use validation of the head-mounted display with imaging and other screens, and headset testing for color accuracy, latency, distortion, contrast, spatial accuracy, ambient light, and live video quality on each compatible headset. The order also requires human factors testing, software verification, electrical and electromagnetic safety, reprocessing validation for reusable components, and labeling that keeps a traditional monitor available as backup.

The risks the FDA identified include software malfunction, use error, tissue malpositioning, latency, prolonged operative time, electrical shock, interference with other devices, and infection.

The first case at Duke Health

Stryker announced on 1 September 2026 that the first procedure using Stryker SportSuite Vision was a hip arthroscopy at Duke Health. Matt Moreau, vice president and general manager of Stryker Sports Medicine, described the product as a step toward a “connected digital operating room.” Chad Mather III, M.D., M.B.A., the orthopedic surgeon at Duke Health who performed the case, said spatial computing let him customize the placement of clinical information inside the sterile field. The release notes that Dr. Mather is a Stryker consultant.

A beachhead, not a general license

The authorization is real, but its scope is easy to overread. It does not extend beyond hip arthroscopy display tasks, does not replace the standard monitor stack for the whole team, and does not authorize diagnostic use of the CT layer. No data yet shows better outcomes than conventional multi-monitor arthroscopy. “Surgical cockpit” is Stryker marketing language, not an FDA device name, and the product page still collects a waitlist, so the September announcement is a first-case report after a mid-July grant rather than a broad commercial rollout.